SINOPHARMA: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
SINOPHARMA
Largest movements
- Cash -€13,906
down €13,906 (-81.7%), from €17,025 to €3,118
mainly Trade debts (-€6,888) and Tax, wage and social debts (-€3,959)
- Receivables within one year +€3,129
up €3,129 (+6.4%), from €49,000 to €52,129
of which Other amounts receivable: +€2,753
- Trade debts -€6,888
down €6,888 (-29.3%), from €23,505 to €16,617
- Tax, wage and social debts -€3,959
down €3,959 (-29.4%), from €13,484 to €9,524
- Profit (loss) carried forward +€3,218
up €3,218 (+31.3%), from -€10,289 to -€7,071
- Other debts -€3,148
down €3,148 (-9.2%), from €34,388 to €31,240
- Gross operating margin +€17,463
up €17,463, from -€5,226 to €12,237
- Taxes +€2,632
new in 2025: €2,632
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €80,923 | €70,146 | -€10,777 | -13.3% |
| Current assets | 29/58 | €80,923 | €70,146 | -€10,777 | -13.3% |
| Stocks and contracts in progress | 3 | €14,898 | €14,898 | = | 0.0% |
| Stocks | 30/36 | €14,898 | €14,898 | = | 0.0% |
| Amounts receivable within one year | 40/41 | €49,000 | €52,129 | +€3,129 | +6.4% |
| Trade receivables | 40 | €6,681 | €7,058 | +€376 | +5.6% |
| Other amounts receivable | 41 | €42,319 | €45,072 | +€2,753 | +6.5% |
| Cash at bank and in hand | 54/58 | €17,025 | €3,118 | -€13,906 | -81.7% |
| Total equity and liabilities | 10/49 | €80,923 | €70,146 | -€10,777 | -13.3% |
| Equity | 10/15 | €9,547 | €12,765 | +€3,218 | +33.7% |
| Contributions | 10/11 | €18,600 | €18,600 | = | 0.0% |
| Reserves | 13 | €1,236 | €1,236 | = | 0.0% |
| Non-distributable reserves | 130/1 | €1,236 | €1,236 | = | 0.0% |
| Reserves not available under the articles | 1311 | €1,236 | €1,236 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€10,289 | -€7,071 | +€3,218 | +31.3% |
| Amounts payable | 17/49 | €71,376 | €57,381 | -€13,995 | -19.6% |
| Amounts payable within one year | 42/48 | €71,376 | €57,381 | -€13,995 | -19.6% |
| Trade debts | 44 | €23,505 | €16,617 | -€6,888 | -29.3% |
| Suppliers | 440/4 | €23,505 | €16,617 | -€6,888 | -29.3% |
| Taxes, remuneration and social security | 45 | €13,484 | €9,524 | -€3,959 | -29.4% |
| Taxes | 450/3 | €13,484 | €9,524 | -€3,959 | -29.4% |
| Other amounts payable | 47/48 | €34,388 | €31,240 | -€3,148 | -9.2% |
| Other operating charges | 640/8 | €553 | €594 | +€41 | +7.5% |
| Gross operating margin | 9900 | -€5,226 | €12,237 | +€17,463 | |
| Operating profit (loss) | 9901 | -€5,779 | €11,643 | +€17,422 | |
| Financial charges | 65/66B | €5,850 | €5,793 | -€57 | -1.0% |
| Recurring financial charges | 65 | €5,850 | €5,793 | -€57 | -1.0% |
| Profit (loss) for the period before taxes | 9903 | -€11,629 | €5,850 | +€17,479 | |
| Income taxes | 67/77 | - | €2,632 | +€2,632 | |
| Profit (loss) for the period | 9904 | -€11,629 | €3,218 | +€14,847 | |
| Profit (loss) for the period to be appropriated | 9905 | -€11,629 | €3,218 | +€14,847 |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 2 October 2026 via checked.be.